Ipamorelin is a synthetic pentapeptide that releases growth hormone by binding the growth hormone secretagogue receptor in the pituitary and hypothalamus, which places it in the ghrelin receptor agonist family rather than among the growth hormone releasing hormone analogs. The honest organizing idea behind every comparison is pulsatile versus direct: ipamorelin and the other secretagogues prompt the body to release its own growth hormone in a feedback-regulated pulse, whereas injected synthetic human growth hormone supplies the hormone at a steady outside level that bypasses that control. None of these secretagogues, ipamorelin included, is FDA-approved for the growth-hormone-promoting uses described in this literature; they are sold in the United States as Research Use Only compounds.
| Mechanism family | Members | What the receptor binding does |
|---|---|---|
| Ghrelin receptor agonists (GHRPs) | Ipamorelin, GHRP-6, GHRP-2, hexarelin | Mimic ghrelin, amplify the natural growth hormone pulse |
| GHRH analogs | CJC-1295, sermorelin | Mimic the hypothalamic signal that sets pulse size |
| Exogenous synthetic HGH | n/a (the hormone itself) | Supplies hormone directly, bypassing feedback |
The published distinction that organizes any ipamorelin comparison is pulsatile-versus-direct, since secretagogues prompt feedback-regulated release of the body's own growth hormone while injected synthetic growth hormone introduces it directly at a steady, feedback-bypassing level.
The literature divides growth hormone secretagogues into two families by the receptor each engages, and ipamorelin's placement is the prerequisite for everything that follows. The ghrelin receptor agonists, also called growth hormone releasing peptides, bind the same growth hormone secretagogue receptor that stomach-derived ghrelin activates, amplifying pituitary release while suppressing somatostatin, the hypothalamic brake on output. Ipamorelin, a five-amino-acid peptide engineered to activate that receptor cleanly, sits firmly on this ghrelin side.
Ipamorelin is documented as a member of the ghrelin receptor agonist family, binding the growth hormone secretagogue receptor and suppressing somatostatin, which is mechanistically separate from the GHRH-analog family represented by sermorelin and CJC-1295.
Within the ghrelin receptor agonist family the members differ mostly by how cleanly they hit the target, and ipamorelin is the outlier toward selectivity. The reported tradeoff runs potency against cleanliness: GHRP-6 carries the strongest appetite stimulation, hexarelin the largest acute pulse, and ipamorelin the least spillover onto appetite, cortisol, and prolactin. This evidence describes pharmacological characterization, not human clinical outcomes, and none of these compounds is FDA-approved for these uses.
| Criteria | GHRP-6 | GHRP-2 | Hexarelin | Ipamorelin |
|---|---|---|---|---|
| Relative potency | Moderate | More potent than GHRP-6 | Highest | Moderate |
| Appetite effect | Pronounced | Mild | Mild | Minimal |
| Cortisol/prolactin | Modest | Raised | Raised | Minimal |
| Receptor desensitization | Lower | Lower | Highest | Lower |
The literature treats ipamorelin as the reference point for a clean growth hormone signal because it releases growth hormone with minimal disturbance to appetite, cortisol, and prolactin, while GHRP-6, GHRP-2, and hexarelin trade that cleanliness for appetite stimulation or greater potency.
The clearest documented line is the receptor each engages: sermorelin and CJC-1295 bind the dedicated growth hormone releasing hormone receptor, while ipamorelin binds the separate ghrelin receptor. Duration is the second axis the record emphasizes, and on it ipamorelin resembles the short-acting sermorelin far more than the long-circulating CJC-1295. The deeper distinction is in pulse shaping, where the releasing hormone analogs set pulse amplitude and ipamorelin amplifies and reinforces it while lifting the somatostatin brake.
Sermorelin and CJC-1295 bind the growth hormone releasing hormone receptor while ipamorelin binds the ghrelin receptor, and because these are independent pathways the literature reports that combining the two produces a response exceeding the sum of either given alone.
The pairing is documented because the two peptides push the same outcome through two different doors: a GHRH analog such as CJC-1295 sets the size of the pulse while ipamorelin amplifies it and suppresses somatostatin, the brake that would otherwise dampen release. The reported result of removing the brake while pressing the accelerator is synergistic rather than additive. Because both peptides prompt the body's own secretion rather than supplying hormone directly, the combination is described as magnifying the natural pulsatile pattern instead of flattening it.
The CJC-1295-with-ipamorelin pairing is documented as synergistic rather than additive because the GHRH analog sets pulse amplitude while ipamorelin amplifies the pulse and suppresses somatostatin, magnifying the body's natural pulsatile pattern rather than flattening it.
The defining documented contrast is between coaxing the body to release its own growth hormone and supplying the hormone from outside. Ipamorelin signals the pituitary to secrete the growth hormone it already makes, so the rise follows the body's pulsatile rhythm and stays subject to the feedback loops, including somatostatin, that regulate the axis. Exogenous synthetic human growth hormone introduces the hormone directly at a dose-set level, producing steadier and often higher exposure that bypasses that governance and does not preserve the pulsatile signature.
| Dimension | Ipamorelin (secretagogue) | Exogenous synthetic HGH |
|---|---|---|
| Source of hormone | Body's own pituitary stores | Introduced directly into circulation |
| Release pattern | Pulsatile, feedback-regulated | Steady, dose-set level |
| Feedback control | Intact, with an inherent ceiling | Bypassed, can exceed natural levels |
Ipamorelin prompts feedback-regulated pulsatile release subject to an inherent ceiling, while exogenous synthetic human growth hormone bypasses that governance to introduce hormone directly at a steady level, making the two categorically different tools rather than interchangeable ones.
Selectivity in this context means ipamorelin activates the growth hormone secretagogue receptor to release growth hormone while leaving neighboring hormonal systems comparatively undisturbed. The older growth hormone releasing peptides hit the same target but spill over, with GHRP-6 producing pronounced appetite stimulation and GHRP-2 and hexarelin tending to raise cortisol and prolactin. The record characterizes ipamorelin for releasing growth hormone with minimal elevation of those off-target hormones, though selectivity is documented as a matter of degree rather than an absolute.
Ipamorelin's selectivity is characterized in the literature as releasing growth hormone with minimal elevation of appetite, cortisol, and prolactin, a cleaner off-target profile than the older GHRP-6, GHRP-2, and hexarelin, though it is described as a matter of degree rather than an absolute.
The off-target hormonal effects fall mostly on the ghrelin receptor side of the divide, and the published profile is the reason the choice of secretagogue is partly a choice about which side effects are acceptable. Appetite stimulation is tied most strongly to GHRP-6, while cortisol and prolactin elevation is associated chiefly with hexarelin and GHRP-2; ipamorelin again stands out for sparing those systems. The GHRH analogs sermorelin and CJC-1295 sit apart from this discussion entirely, because acting through the releasing hormone receptor they do not characteristically provoke appetite, cortisol, or prolactin responses.
Appetite stimulation is most strongly associated with GHRP-6 and cortisol and prolactin elevation chiefly with hexarelin and GHRP-2, while ipamorelin is documented as sparing those systems and the GHRH analogs do not characteristically provoke them at all; all such effects are reported off-target burdens, not approved therapeutic profiles.
Potency and desensitization are documented as trading off against each other among the ghrelin receptor agonists. Hexarelin is the most potent, producing the largest acute growth hormone release, but it is also the most prone to receptor desensitization, the receptor's adaptive downregulation under strong, repeated stimulation, which is the main reason the most potent option is not automatically the best for sustained use. Ipamorelin is more moderate in potency but is regarded as gentler on the receptor, which the literature frames as better suited to ongoing dosing where preserving responsiveness matters more than maximizing any single pulse.
Hexarelin is documented as the most potent ghrelin receptor agonist but the most prone to receptor desensitization, while ipamorelin's moderate potency and lower desensitization tendency are reported as the more practical combination for steady, repeatable use over time.
Educational use only. This article describes what the published scientific and clinical literature reports about Ipamorelin. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
